Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary lung carcinoma~  * Non-squamous histology~ * Advanced disease defined as stage IIIB disease with cytologically documented malignant pleural or pericardial effusion or stage IV disease~* Available pathology block or unstained slides from initial or subsequent diagnosis~  * Must have undergone ≥ 1 core biopsy~ * No patients whose diagnosis was made through a fine-needle aspirate~* No uncontrolled pleural effusions, ascites, or third-space fluid collections~* Meets 1 of the following criteria:~  * Non-smoker, defined as patients who smoked ≤ 100 cigarettes in their lifetime~ * Former light smoker, defined as patients who smoked between \> 100 cigarettes AND ≤ 10 pack-years AND quit ≥ 1 year ago~* No known central nervous system disease, except for treated brain metastases meeting the following criteria:~  * No evidence of progression or hemorrhage after treatment~ * No ongoing requirement for dexamethasone as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period~ * Stable doses of anticonvulsants are allowed~ * Treatment for brain metastases may include whole-brain radiotherapy, radiosurgery (gamma knife, LINAC, or equivalent), or a combination as deemed appropriate by the treating physician~ * No patients with central nervous system (CNS) metastases treated by neurosurgical resection~ * No brain biopsy within the past 3 months~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1~* Absolute neutrophil count (ANC) ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9.0 g/dL~* Total bilirubin ≤ 1.5 times upper limit of normal (ULN)~* Aspartate aminotransferase (AST/ALT) ≤ 2.5 times ULN~* Calculated creatinine clearance \> 45 mL/min OR creatinine ≤ 1.5 times ULN~* Prothrombin time ≤ 1.5 times ULN~* Partial thromboplastin time ≤ ULN~* Urine protein:creatinine ratio ≤ 1.0~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Patients with a history of hypertension are eligible provided it is well controlled (BP \< 150/100 mm Hg) on a stable regimen of antihypertensive therapy~  * No history of hypertensive crisis or hypertensive encephalopathy~* Able and compliant with folic acid and B12 supplementation~* Able to swallow tablets intact or dissolved in water~* No dysphagia or active gastrointestinal (GI) disease or disorder that alters GI motility or absorption~* No lack of integrity of the GI tract (e.g., a significant surgical resection of the stomach or small bowel)~* No abdominal fistula, GI perforation, or intraabdominal abscess within the past 6 months~* None of the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure (NYHA class II-IV)~ * Cardiac arrhythmia~ * Psychiatric illness, social situations, or any other medical condition that would limit compliance with study requirements~* No myocardial infarction or other evidence of arterial thrombotic disease (angina) within the past 6 months~* No history of cerebral vascular accident or transient ischemic attack within the past 6 months~* No significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within the past 6 months~* No history of bleeding diathesis or coagulopathy~* No ongoing hemoptysis, defined as ≥ ½ teaspoon of bright red blood~  * Patients with procedure-related hemoptysis that has resolved post-procedure are eligible~* No serious nonhealing wound, ulcer, bone fracture, or significant traumatic injury within the past 28 days~* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy~  * Patient must be chemotherapy naive~ * Prior neoadjuvant or adjuvant chemotherapy allowed provided it was completed ≥ 6 months ago~* No prior anti-vascular endothelial growth factor therapy~* At least 3 weeks since prior major surgery~* At least 1 week since prior radiotherapy~* More than 28 days since prior and no concurrent treatment with an investigational agent~* More than 7 days since prior core biopsy~* Concurrent daily treatment with aspirin or NSAIDs are eligible provided patients are able to interrupt NSAIDs 2 days before (5 days for long-acting NSAIDs), the day of, and for 2 days following the administration of pemetrexed disodium~* No concurrent treatment with dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix), and/or cilostazol (Pletal)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm Trial (Type: OTHER): Bevacizumab, Carboplatin, and Pemetrexed disodium, with option for second line erlotinib hydrochloride

Based on this trial design, predict the completion outcome and termination type (if applicable).